olivLaw · US equity research
GSK plc GSK
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
GSK plc is a biopharmaceutical company focused on specialty medicines and vaccines, with emphasis on respiratory, immunology, inflammation, oncology and HIV. Sales in fiscal 2025 exceeded £32 billion, and the company is in a leadership transition while accelerating its pipeline, which matters for investor expectations.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, GSK plc (GSK) stock was 51.15 USD (+5.03% on the day), with beta 0.24, 52-week range 46.11–61.18 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 58.9
- strong (55–70)
- Bollinger (20, 2)
- 45.96 – 52.31
- in the upper half of the band · %B 0.82 · band width 12.9%
- SMA 50 / 200
- 49.29 / 52.36
- mixed trend
- MACD (12, 26, 9)
- 0.24 / 0.16
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +9.9% | −1.1% | +11.0 pp | — |
| 3 months | −0.6% | −0.5% | −0.2 pp | — |
| 6 months | +1.2% | +4.4% | −3.2 pp | — |
| Year to date | +4.3% | +12.3% | −8.0 pp | — |
| 1 year | +9.2% | +13.5% | −4.3 pp | +19.3% |
| 3 years | +48.5% | +76.4% | −27.9 pp | +13.0% |
| 5 years | +17.6% | +63.7% | −46.1 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.8 bn | 33.8 bn | 24.4 bn | 24.7 bn | 29.3 bn | 30.3 bn | 31.4 bn | 32.7 bn |
| Revenue YoY | +2.1% | +9.5% | −27.8% | +1.4% | +18.7% | +3.4% | +3.5% | +4.1% |
| Net income | 3.6 bn | 4.6 bn | 5.7 bn | 4.4 bn | 15.0 bn | 4.9 bn | 2.6 bn | 5.7 bn |
| Net income YoY | +136.5% | +28.2% | +23.8% | −23.7% | +241.1% | −67.1% | −47.7% | +122.0% |
| Diluted EPS | 0.73 | 0.93 | 1.43 | 1.08 | 3.66 | 1.20 | 0.62 | 1.39 |
| Diluted EPS YoY | +135.2% | +27.0% | +54.0% | −24.1% | +238.4% | −67.3% | −48.1% | +123.2% |
| net % | 11.8% | 13.8% | 23.6% | 17.8% | 51.0% | 16.2% | 8.2% | 17.5% |
| Free cash flow | 7.1 bn | 6.8 bn | 7.5 bn | 7.0 bn | 6.3 bn | 5.5 bn | 5.2 bn | 6.4 bn |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 3.4 bn GBP
- Financial debt
- 17.7 bn GBP
- Net debt
- 14.3 bn GBP
- Equity
- 16.0 bn GBP
- Total assets
- 61.1 bn GBP
- Debt / equity
- 1.11x
- Current ratio
- 0.82x
- ROE
- 39.4%
- ROA
- 9.5%
- FCF margin
- 19.6%
Financial statements (source on every figure)
Revenue and net income (GBP)
Margins
Income statement · GBP
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 24.4 bn | 24.7 bn | 29.3 bn | 30.3 bn | 31.4 bn | 32.7 bn | SEC (XBRL)· 06 Mar 2026verified |
| Cost of revenue | 7.9 bn | 8.2 bn | 9.6 bn | 8.6 bn | 9.0 bn | 9.0 bn | SEC (XBRL)· 06 Mar 2026verified |
| Gross profit | 16.4 bn | 16.5 bn | 19.8 bn | 21.8 bn | 22.3 bn | 23.7 bn | SEC (XBRL)· 06 Mar 2026verified |
| Research & development | 4.8 bn | 5.0 bn | 5.5 bn | 6.2 bn | 6.4 bn | 7.5 bn | SEC (XBRL)· 06 Mar 2026verified |
| Operating income | 6.0 bn | 4.4 bn | 6.4 bn | 6.7 bn | 4.0 bn | 7.9 bn | SEC (XBRL)· 06 Mar 2026verified |
| Depreciation & amortisation | 2.1 bn | 2.1 bn | 2.1 bn | 2.3 bn | 2.6 bn | 2.3 bn | SEC (XBRL)· 06 Mar 2026verified |
| EBITDA | 8.0 bn ≈ | 6.5 bn ≈ | 8.6 bn ≈ | 9.0 bn ≈ | 6.6 bn ≈ | 10.2 bn ≈ | SEC (XBRL)· 06 Mar 2026derived |
| Interest expense | 874.0 m | 769.0 m | 879.0 m | 792.0 m | 669.0 m | 701.0 m | SEC (XBRL)· 06 Mar 2026verified |
| Pre-tax income | 5.2 bn | 3.6 bn | 5.6 bn | 6.1 bn | 3.5 bn | 7.4 bn | SEC (XBRL)· 06 Mar 2026verified |
| Income tax | 67.0 m | 83.0 m | 707.0 m | 756.0 m | 526.0 m | 1.1 bn | SEC (XBRL)· 06 Mar 2026verified |
| Net income | 5.7 bn | 4.4 bn | 15.0 bn | 4.9 bn | 2.6 bn | 5.7 bn | SEC (XBRL)· 06 Mar 2026verified |
| Diluted EPS | 1.43 | 1.08 | 3.66 | 1.20 | 0.62 | 1.39 | SEC (XBRL)· 06 Mar 2026verified |
| Weighted average diluted shares | 4.0 bn | 4.1 bn | 4.1 bn | 4.1 bn | 4.1 bn | 4.1 bn | SEC (XBRL)· 06 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · GBP
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 6.3 bn | 4.3 bn | 3.7 bn | 2.9 bn | 3.9 bn | 3.4 bn | SEC (XBRL)· 06 Mar 2026verified |
| Receivables | 7.0 bn | 7.9 bn | 7.1 bn | 7.4 bn | 6.8 bn | 7.5 bn | SEC (XBRL)· 06 Mar 2026verified |
| Inventories | 6.0 bn | 5.8 bn | 5.1 bn | 5.5 bn | 5.7 bn | 5.9 bn | SEC (XBRL)· 06 Mar 2026verified |
| Current assets | 20.2 bn | 18.7 bn | 20.8 bn | 18.6 bn | 17.0 bn | 17.5 bn | SEC (XBRL)· 06 Mar 2026verified |
| Property, plant & equipment, net | 10.2 bn | 9.9 bn | 8.9 bn | 9.0 bn | 9.2 bn | 9.3 bn | SEC (XBRL)· 06 Mar 2026verified |
| Goodwill | 10.6 bn | 10.6 bn | 7.0 bn | 6.8 bn | 7.0 bn | 7.0 bn | SEC (XBRL)· 06 Mar 2026verified |
| Intangibles (excl. goodwill) | 29.8 bn | 30.1 bn | 14.3 bn | 14.8 bn | 15.5 bn | 16.7 bn | SEC (XBRL)· 06 Mar 2026verified |
| Total assets | 80.4 bn | 79.1 bn | 60.1 bn | 59.0 bn | 59.5 bn | 61.1 bn | SEC (XBRL)· 06 Mar 2026verified |
| Accounts payable | 15.8 bn | 17.6 bn | 16.3 bn | 15.8 bn | 15.3 bn | 15.4 bn | SEC (XBRL)· 06 Mar 2026verified |
| Short-term debt | 3.7 bn | 3.6 bn | 4.0 bn | 2.8 bn | 2.3 bn | 3.0 bn | SEC (XBRL)· 06 Mar 2026verified |
| Long-term debt | 23.4 bn | 20.6 bn | 17.0 bn | 15.2 bn | 14.6 bn | 14.7 bn | SEC (XBRL)· 06 Mar 2026verified |
| Current liabilities | 22.1 bn | 23.7 bn | 22.8 bn | 21.1 bn | 21.7 bn | 21.4 bn | SEC (XBRL)· 06 Mar 2026verified |
| Total liabilities | 59.6 bn | 57.8 bn | 50.1 bn | 46.2 bn | 46.4 bn | 45.2 bn | SEC (XBRL)· 06 Mar 2026verified |
| Equity | 20.8 bn | 21.3 bn | 10.1 bn | 12.8 bn | 13.1 bn | 16.0 bn | SEC (XBRL)· 06 Mar 2026verified |
| Shares outstanding at year end | 5.4 bn | 5.4 bn | 4.3 bn | 4.3 bn | 4.3 bn | 4.3 bn | SEC (XBRL)· 06 Mar 2026verified |
Cash flow · GBP
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 8.4 bn | 8.0 bn | 7.4 bn | 6.8 bn | 6.6 bn | 7.7 bn | SEC (XBRL)· 06 Mar 2026verified |
| Capex | 989.0 m | 950.0 m | 1.1 bn | 1.3 bn | 1.4 bn | 1.3 bn | SEC (XBRL)· 06 Mar 2026verified |
| Free cash flow | 7.5 bn ≈ | 7.0 bn ≈ | 6.3 bn ≈ | 5.5 bn ≈ | 5.2 bn ≈ | 6.4 bn ≈ | SEC (XBRL)· 06 Mar 2026derived |
| Investing cash flow | 2.2 bn | -1.8 bn | -8.8 bn | -1.6 bn | -1.2 bn | -4.2 bn | SEC (XBRL)· 06 Mar 2026verified |
| Financing cash flow | -10.1 bn | -7.6 bn | 823.0 m | -5.6 bn | -4.7 bn | -3.7 bn | SEC (XBRL)· 06 Mar 2026verified |
| Share repurchases | — | — | — | 0 | 0 | 1.4 bn | SEC (XBRL)· 06 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 55 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
- Balance sheet52
- Growth15
- Quality88
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Neutral profile · Score 55/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 23.9% | 92 (vs peers) | 17% |
| Net margin · Quality | 17.5% | 68 (vs peers) | 10% |
| FCF conversion · Quality | 111.8% | 100 (on a fixed band) | 10% |
| Revenue CAGR 3Y · Growth | 3.7% | 31 (on a fixed band) | 14% |
| EPS CAGR 3Y · Growth | -27.6% | 0 (on a fixed band) | 14% |
| Net debt / EBITDA · Balance sheet | 1.4x | 43 (vs peers) | 17% |
| Interest coverage · Balance sheet | 11.3x | 100 (on a fixed band) | 10% |
| Current ratio · Balance sheet | 0.8x | 2 (on a fixed band) | 7% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet52/100 · 3/3 factors with a value
- Growth15/100 · 2/2 factors with a value
- Quality88/100 · 3/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
GSK plc (GSK). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 32.7 bn GBP in 2025; YoY growth 4.1%; net margin 17.5%; ROE 38.0%; net debt/EBITDA 1.4x.
The estimated value range is 22.33–55.49 GBP per share (median of 2 methods, agreement: same basis (multiples on one peer group, not independent confirmations)); assumptions are illustrative. The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 55/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns, valuation. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 23.9%
- FCF conversion: 111.8%
- Interest coverage: 11.3x
What contradicts it
- EPS CAGR 3Y: -27.6%
- Current ratio: 0.8x
Not assessed (insufficient data or a ratio without meaning): P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| TGTXTg Therapeutics, Inc. | 9.4 bn | 22.5 | 100.3% | 55.2% | +87.3% | +85% / +381% |
| BLRXBioLineRx Ltd | 4.9 bn | — | -12.8% | -171.7% | −95.9% | −46% / −97% |
| BHCBausch Health Companies Inc. | 3.1 bn | — | — | -7.6% | +6.7% | +31% / +17% |
| ANABAnaptysbio, Inc. | 1.4 bn | 11.5 | — | 82.4% | +157.0% | +71% / +404% |
| KURAKura Oncology, Inc. | 677.0 m | — | -167.7% | -384.3% | +25.2% | −37% / −21% |
| DMACDiaMedica Therapeutics Inc. | 580.8 m | — | -114.6% | — | unavailable | +25% / +341% |
| PHATPhathom Pharmaceuticals, Inc. | 461.7 m | — | — | -30.2% | +216.9% | −64% / −19% |
| ALTAltimmune, Inc. | 412.4 m | — | -28.9% | -223,804.9% | +105.0% | −60% / −33% |
1- and 3-year price returns: for GSK from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Mar 2026; since then the company filed 6-K (02 Nov 2026), 6-K (28 Oct 2026), 6-K (26 Oct 2026).
In brief
GSK plc is a biopharmaceutical company focused on specialty medicines and vaccines, with emphasis on respiratory, immunology, inflammation, oncology and HIV. Sales in fiscal 2025 exceeded £32 billion, and the company is in a leadership transition while accelerating its pipeline, which matters for investor expectations.
SWOT
Strengths
- A strong specialty medicines portfolio with accelerated growth and a pipeline strengthened through acquisitions and partnerships.
- Long-standing expertise in the science of the immune system, particularly in respiratory and inflammation.
- Strong cash generation that supports R&D investment and shareholder returns.
Weaknesses
- Dependence on a limited number of key products and the expiry of exclusivity for important molecules.
- Long-term weak share price performance, which management acknowledges as significant.
- The General Medicines segment is declining, which weighs on the overall growth profile.
Opportunities
- New launches in oncology and respiratory could open significant growth if they are confirmed in clinical practice.
- Technology and AI could accelerate discovery and reduce R&D costs if integrated at scale.
- Development of therapies for fibrotic diseases of the lung, liver and kidney could extend addressable markets.
Threats
- Continued pricing pressure in the US and Europe could reduce long-term margins.
- Trade tensions and possible tariffs on pharmaceutical imports could raise production costs.
- Competition from licensed assets from China could intensify rivalry in key indications.
Risks
- Loss of exclusivityhigh
The expiry of exclusivity for dolutegravir could significantly reduce revenues if not offset by new launches.
- Pricing pressurehigh
Pricing agreements with governments, particularly the US Administration, could limit revenues in key markets.
- Clinical trial failuremedium
Negative results in late-stage programmes could affect pipeline value and growth plans.
- Trade and supply chain risksmedium
Tariff measures and supply chain reconfiguration could increase costs and disrupt deliveries.
- AI and data riskslow
Use of data and AI may raise privacy, security and trust concerns with reputational impact.
Investment thesis
What would need to be true (bull case)
- Strong growth in specialty medicines and a strengthened pipeline could support sustainable growth if new launches are executed well.
- Solid cash generation and a recovering dividend suggest the investment and shareholder return plan can be funded.
- Expertise in immune system science and use of technology could improve R&D efficiency and reduce project risk.
What would break the thesis
- Continued US pricing pressure and tariff risk could limit margins even if sales grow.
- The expiry of exclusivity for a major product could create a revenue gap that is hard to fill quickly.
- Long-term weak share price performance suggests the market may be sceptical about strategy execution.
What to watch
- Performance of new launches in respiratory and oncology2026
- Impact of the US Administration pricing agreement on sales2026
- Progress of late-stage pipeline and pivotal readouts2026
- Pace of acquisitions and development agreementsnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Mar 2026; since then the company filed 6-K (02 Nov 2026), 6-K (28 Oct 2026), 6-K (26 Oct 2026).
The business
According to its 2025 annual report filed with the SEC, GSK describes its strategy as a focused biopharma company following the Haleon demerger in 2022, which allowed a reset balance sheet for investment in innovation. Total sales grew to more than £32 billion in 2025 1, and total R&D expense reached £7.5 billion 1. The company reports five major product approvals in 2025 1.
The company has a portfolio across specialty medicines, vaccines and general medicines. A new CEO, Luke Miels, took over, and stated priorities include executing new launches, accelerating late-stage assets and using technology, including AI, in R&D and manufacturing 1.
The long-term strategy targets growth ambitions for 2031 and addresses the loss of dolutegravir exclusivity. The pipeline has been strengthened through acquisitions and partnerships, notably in RI&I and oncology, and 58 assets are in the pipeline 1.
Segments
Specialty Medicines
Specialty Medicines sales grew 14% AER and 17% CER in 2025, with double-digit growth in oncology, respiratory, immunology and inflammation, and HIV 1. The segment is the main growth driver.
Vaccines and General Medicines
Vaccines sales were stable at AER and up at CER, while General Medicines declined, showing different dynamics between the two lines 1.
Research and Development
R&D is organised around four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. The company began six phase I programmes and had seven positive phase III readouts in 2025 1.
Market context
The global medicine market is expected to reach about $2.4 trillion by 2029 1. Specialty medicines' share of global spending is projected to rise significantly, which supports the company's strategy. Pricing pressure in the US and trade uncertainty could however affect margins.
The regulatory and pricing environment remains dynamic: in December 2025 the company reached a pricing agreement with the US Administration, and tariff policies and supply chain decisions could change market conditions.
Trends
- Pricing pressureheadwind
The US Administration is seeking to lower drug prices by tying them to international levels, which could reduce revenues in the US market if the pressure extends.
- Burden of chronic diseasetailwind
Chronic diseases, cancer and respiratory conditions are projected to remain among the top disease burdens, supporting demand for the company's therapies.
- Artificial intelligence in R&Dmixed
AI could accelerate drug discovery and development, but realising these benefits depends on talent and public trust in how data is used.
- Trade tensions and supply chainsmixed
Tariff policies and reshoring of production in the US and EU could add costs, though a stable zero-tariff arrangement for UK-made products offers some predictability.
Competitive position
The source material points to competition from companies developing therapies in the same areas, especially oncology and respiratory, where innovation is rapid. Chinese licensing activity has grown significantly, which could intensify competition for new molecules.
The company aims to compete through best-in-class or first-in-class medicines, saying over 75% of its assets have this potential, but success depends on clinical results and launch execution.
- Chinese biopharma companies with licensed assets
Chinese assets make up a growing share of licensing deals and such companies could compete directly in the same indications.
- Hengrui Pharma
Hengrui is named as a partner in a multi-medicine agreement in RI&I and oncology, and therefore also a competitor in the same areas.
- Companies with anti-IL-5 and asthma therapies
The company markets treatments for asthma and COPD, a market in which other pharmaceutical companies hold competing products.
- Developers of liver and metabolic therapies
Companies working on liver disease and MASH compete for the company's hepatology pipeline assets.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)28 Oct 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)21 Oct 2026
- Current report (foreign issuer)19 Oct 2026
- Current report (foreign issuer)19 Oct 2026
- Current report (foreign issuer)15 Oct 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / GSK plc · 06 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.